Ontology highlight
ABSTRACT:
SUBMITTER: Burnell M
PROVIDER: S-EPMC2799234 | biostudies-literature | 2010 Jan
REPOSITORIES: biostudies-literature
Burnell Margot M Levine Mark N MN Chapman Judith-Anne W JA Bramwell Vivien V Gelmon Karen K Walley Barbara B Vandenberg Ted T Chalchal Haji H Albain Kathy S KS Perez Edith A EA Rugo Hope H Pritchard Kathleen K O'Brien Patti P Shepherd Lois E LE
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091109 1
PURPOSE Cyclophosphamide, epirubicin, and fluorouracil (CEF) and doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) are commonly used adjuvant regimens in women with early breast cancer. In a previous trial in women with locally advanced breast cancer, 3 months of high-dose epirubicin and cyclophosphamide (EC) administered every 2 weeks (dose-dense) was equivalent to 6 months of CEF. We hypothesized that 3 months of paclitaxel after dose-dense EC (EC/T) would be superior to CEF or ...[more]